Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 4
1987 1
1988 3
1989 7
1990 8
1991 3
1992 6
1993 5
1994 5
1995 4
1996 1
1997 6
1998 3
1999 7
2000 1
2001 2
2002 5
2003 7
2004 13
2005 10
2006 10
2007 8
2008 12
2009 5
2010 5
2011 5
2012 10
2013 8
2014 1
2015 1
2016 2
2017 5
2018 3
2019 4
2020 2
2021 5
2022 5
2023 3
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo MJ, Wortman JR, Wu H, Auniņš JG, McChalicher CWJ, Winkler JA, McGovern BH, Trucksis M, Henn MR, von Moltke L. Feuerstadt P, et al. Among authors: lashner b. N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516. N Engl J Med. 2022. PMID: 35045228 Clinical Trial.
Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. Among authors: lashner ba. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Free article. Clinical Trial.
Changes, Changes, Changes.
Lashner B, Cominelli F, Petrylak A, Heller C. Lashner B, et al. Inflamm Bowel Dis. 2017 Dec 19;24(1):1. doi: 10.1093/ibd/izx074. Inflamm Bowel Dis. 2017. PMID: 29272496 No abstract available.
Conflicts of Interest in Clinical Practice Guidelines.
Lashner BA, Cominelli F. Lashner BA, et al. Inflamm Bowel Dis. 2019 Mar 14;25(4):646. doi: 10.1093/ibd/izy317. Inflamm Bowel Dis. 2019. PMID: 30295815 Free PMC article. No abstract available.
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events.
Shatila M, Zhang HC, Shirwaikar Thomas A, Machado AP, Naz S, Mittal N, Catinis C, Varatharajalu K, Colli Cruz C, Lu E, Wu D, Brahmer JR, Carbonnel F, Hanauer SB, Lashner B, Schneider B, Thompson JA, Obeid M, Farris DP, Wang Y. Shatila M, et al. Among authors: lashner b. J Immunother Cancer. 2024 Nov 14;12(11):e009742. doi: 10.1136/jitc-2024-009742. J Immunother Cancer. 2024. PMID: 39542654 Free PMC article.
Gastrointestinal manifestations of COVID-19.
El Ouali S, Achkar JP, Lashner B, Regueiro M. El Ouali S, et al. Among authors: lashner b. Cleve Clin J Med. 2021 Feb 17. doi: 10.3949/ccjm.87a.ccc049. Online ahead of print. Cleve Clin J Med. 2021. PMID: 32554734 Free article.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS; ECOSPOR III and ECOSPOR IV investigators. Kraft CS, et al. Among authors: lashner b. Infect Dis Ther. 2024 Oct;13(10):2105-2121. doi: 10.1007/s40121-024-01007-z. Epub 2024 Jun 28. Infect Dis Ther. 2024. PMID: 38941068 Free PMC article.
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Berenson CS, Lashner B, Korman LY, Hohmann E, Deshpande A, Louie TJ, Sims M, Pardi D, Kraft CS, Wang EEL, Cohen SH, Feuerstadt P, Oneto C, Misra B, Pullman J, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Lee CH. Berenson CS, et al. Among authors: lashner b. Clin Infect Dis. 2023 Nov 30;77(11):1504-1510. doi: 10.1093/cid/ciad448. Clin Infect Dis. 2023. PMID: 37539715 Free PMC article. Clinical Trial.
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, Hohmann EL, Wang EEL, Oneto C, Cohen SH, Berenson CS, Korman L, Lee C, Lashner B, Kraft CS, Ramesh M, Silverman M, Pardi DS, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L; ECOSPOR IV Investigators. Sims MD, et al. Among authors: lashner b. JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/jamanetworkopen.2022.55758. JAMA Netw Open. 2023. PMID: 36780159 Free PMC article. Clinical Trial.
192 results